Emcure Pharmaceuticals
add_icon

Emcure Pharmaceuticals

1,471.60
-6.60
(-0.45%)
Market Cap
27,896.36 Cr
PE Ratio
31.30
Volume
1,20,178.00
Day High - Low
1,486.00 - 1,443.80
52W High-Low
1,585.60 - 889.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
27,896.36 Cr
EPS
36.43
PE Ratio
31.30
PB Ratio
5.91
Book Value
250.15
EBITDA
1,541.60
Dividend Yield
0.20 %
Industry
Healthcare
Return on Equity
15.24
Debt to Equity
0.45
Analyst Rating and Forecast
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+83.33 %
+83.33 %
Hold
Hold+16.67 %
+16.67 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Emcure Pharmaceuticals responds to BSE query on share volume increase, stating it's market-driven with no undisclosed material events requiring regulatory disclosure.
positive
Emcure Pharmaceuticals board approves appointment of C S Muralidharan as Independent Director effective April 01, 2026, subject to shareholder approval through postal ballot.
positive
Emcure Pharmaceuticals allotted 17,000 equity shares to employees under ESOS 2013 scheme, increasing paid-up capital to Rs. 1,89,58,95,470 from Rs. 1,89,57,25,470.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,758.40
#1 4,21,899.06
38.94
#1 54,729.00
9.71
#1 10,980
16.07
49.38
6,013.50
1,59,639.53
65.35
9,712.00
18.67
2,191
-1.02
40.11
4,213.90
1,42,617.52
63.57
11,539.40
6.99
1,911
26.24
45.74
2,296.70
1,04,912.98
22.73
22,909.50
13.74
3,306
#1 37.44
52.63
1,253.30
1,04,604.22
19.63
33,741.20
16.73
5,725
-15.28
43.17
1,221.80
98,693.56
22.38
28,409.50
7.12
5,291
-57.18
26.47
860.60
86,596.50
#1 17.83
23,511.00
18.55
4,615
-0.32
37.77
1,927.40
79,564.05
45.78
12,744.20
#1 20.90
2,007
7.65
32.45
1,278.70
74,267.10
21.52
32,345.60
9.43
3,484
7.59
57.83
5,144.50
61,510.21
25.95
13,458.30
3.70
2,216
1.90
33.49
Growth Rate
Revenue Growth
18.67 %
Net Income Growth
34.10 %
Cash Flow Change
-22.38 %
ROE
-9.82 %
ROCE
-1.72 %
EBITDA Margin (Avg.)
0.99 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,967
2,121
2,104
2,273
2,365
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,608
1,724
1,687
1,794
1,909
EBITDA
311
327
316
323
360
417
359
397
417
479
456
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
20 %
21 %
19 %
Depreciation
67
70
84
91
94
97
97
97
100
105
105
Interest
52
59
61
66
59
46
32
39
27
33
38
Profit Before Tax
191
198
171
167
207
273
230
261
291
341
314
Tax
50
52
51
46
55
72
74
63
76
90
82
Net Profit
141
146
120
121
153
202
156
197
215
251
231
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97
10.92
12.85
12.16

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
3,197
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
4,556
Capital Work in Progress
531
581
485
302
320
411
159
177
Investments
0
0
0
0
25
25
318
95
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
4,763
Total Equity & Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
8,233
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
2,668
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
923
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
4,642
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
4,257
Share Capital
181
181
181
181
181
181
181
190

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-700
32
259
42
134
219
-58
Investing Activities
-409
-168
-257
-575
-468
-715
-96
Operating Activities
444
500
704
768
747
1,097
852
Financing Activities
-735
-301
-189
-152
-145
-164
-814

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
77.91 %
77.88 %
77.87 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
2.86 %
3.29 %
3.59 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
2.84 %
4.37 %
6.10 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
5.95 %
6.24 %
6.46 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
10.44 %
8.22 %
5.98 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671
1,33,549
1,26,169
1,18,863

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 3 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.2 0.00

Announcements

Clarification On Volume Movement LetterMar 10, 2026
Clarification sought from Emcure Pharmaceuticals LtdMar 10, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementMar 09, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On March 09 2026.Mar 09, 2026
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 03, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 02, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 20, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 18, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 17, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 10, 2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - Incident Of Fire At Our Manufacturing Plant Located At Hinjawadi Pune MaharashtraFeb 07, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 04, 2026
Disclosure Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Feb 04, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 04, 2026
Appointment of Company Secretary and Compliance OfficerFeb 04, 2026
Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Nine Months Ended December 31 2025.Feb 04, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On February 04 2026.Feb 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 22, 2026
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2025Jan 22, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Update On US FDA Inspection At Our Manufacturing Facility Located At Kadu Surendranagar Gujarat India.Dec 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 22, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 01, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Search And Seizure/ Inspection Operation Conducted By The Goods & Service Tax Department Mumbai Maharashtra.Nov 27, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerNov 21, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 19, 2025
Intimation Of Receipt Of No-Objection Letter For Reclassification Of Shareholding From Promoter And Promoter Group Category To Public Category In Accordance With Regulation 31A Of The Securities And Exchange Board Of India (Listing Obligations And DisclosNov 18, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Board Meeting Outcome for Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Half-Year Ended September 30 2025Nov 11, 2025
Unaudited Financial Results For The Quarter And Half-Year Ended September 30 2025Nov 11, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 03, 2025
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30 2025Nov 03, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 17, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At Our Manufacturing Facility Located At Kadu Surendranagar Gujarat India.Oct 10, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Intimation Of Withdrawal Of Re-Classification Application Under Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Oct 07, 2025
Intimation Of Change In Email Address Of MUFG Intime India Private Limited Registrar And Share Transfer Agent Of The Company.Oct 06, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 03, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 29, 2025
Closure of Trading WindowSep 26, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
2.80%
8535
0.11%
1.06%
UTI Nifty500 Shariah Index Fund Direct-Growth
0.08%
358
0.08%
0.08%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
350
0.00%
0.02%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
15
0.00%
0.03%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.08%
-7
0.00%
0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.02%
-1
0.00%
0.02%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.02%
1
0.00%
0.00%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.00%
0
0.00%
0.00%
Franklin India Opportunities Direct Fund-Growth
0.00%
0
0.00%
0.00%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
3.03%
0
0.00%
-0.17%
Aditya Birla Sun Life Retirement Fund - The 30s Plan Direct-Growth
1.13%
0
0.00%
-0.01%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.30%
0
0.00%
-0.01%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
0
0.00%
0.00%
Axis Balanced Advantage Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Business Cycles Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Equity Savings Fund Direct-Growth
0.36%
0
0.00%
0.00%
Axis Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Nifty 500 Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Healthcare Fund Direct-Growth
3.79%
0
0.00%
-0.12%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.32%
0
0.00%
-0.03%
Bandhan Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Healthcare Fund Direct - Growth
0.00%
0
0.00%
0.00%
Bandhan Midcap Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
49.52
ATR(14)
Less Volatile
59.26
STOCH(9,6)
Neutral
44.27
STOCH RSI(14)
Neutral
47.08
MACD(12,26)
Bullish
0.69
ADX(14)
Weak Trend
13.34
UO(9)
Bearish
41.90
ROC(12)
Uptrend And Accelerating
0.77
WillR(14)
Neutral
-52.49

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes...more
Listing Date
10 Jul, 2024(1 Years, 41 days)
Chairperson NameBerjis M Desai